Overview

A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease

Status:
Active, not recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company